Home New England Boston, MA NFlection Therapeutics, Inc. COMPANY
Clinical Phase 2
Also known as NFlection Therapeutics · 2 sources
NFlection Therapeutics is a clinical-stage biotechnology company developing targeted therapies for skin disorders driven by aberrant RAS pathway activation. From company website Source · Oct 12, 2026
Keywords: oncology neurofibromatosis squamous cell carcinoma Cutaneous Neurofibroma Neurofibromatosis 1 NFX-179 Show all 6 keywords
Location: Boston, MA · source · Oct 14, 2026
Profile checked Oct 10, 2026
At a glance HQ Boston, MA source Region New England Stage Clinical Phase 2 Latest trial Phase 2: NFX-179 Topical Gel Treatment for Adults With Neurofibromatosis 1 (NF1) and Cutaneous Neurofibromas (… (Sep 29, 2021) source Timeline Sep 29, 2021 Trial start Phase 2: NFX-179 Topical Gel Treatment for Adults With Neurofibromatosis 1 (NF1) and Cutaneous Neurofibromas (cNF) source ↗ Aug 21, 2020 Trial start Phase 2: NFX-179 Topical Gel Treatment in Adults With Neurofibromatosis 1 (NF1) and Cutaneous Neurofibromas (cNF) source ↗ Clinical trials (lead sponsor) 2 Record Title Phase Status Start Primary completion NCT05005845 NFX-179 Topical Gel Treatment for Adults With Neurofibromatosis 1 (NF1) and Cutaneous Neurofibromas (cNF) Phase 2 Completed Sep 29, 2021 Oct 2, 2023 (actual) NCT04435665 NFX-179 Topical Gel Treatment in Adults With Neurofibromatosis 1 (NF1) and Cutaneous Neurofibromas (cNF) Phase 2 Completed Aug 21, 2020 Apr 8, 2021 (actual)
